Patents Assigned to Genfit
  • Methods of treatment of cholestatic diseases
    Patent number: 11857523
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: June 20, 2023
    Date of Patent: January 2, 2024
    Assignee: Genfit
    Inventor: Remy Hanf
  • Methods of treatment of cholestatic diseases
    Patent number: 11850223
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: June 20, 2023
    Date of Patent: December 26, 2023
    Assignee: Genfit
    Inventor: Remy Hanf
  • Automated pattern recognition and scoring method of histological images
    Patent number: 11676269
    Abstract: The present invention relates to a novel automated pattern recognition and scoring method of histological images.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: June 13, 2023
    Assignee: GENFIT
    Inventors: John Brozek, Nathalie Degallaix, Benoit Noel, Elton Rexhepaj
  • Pharmaceutical compositions for combination therapy
    Patent number: 11590108
    Abstract: The present invention relates to a combination of active ingredients for use in the treatment of diseases.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: February 28, 2023
    Assignee: Genfit
    Inventors: Emeline Descamps, Robert Walczak, Carole Belanger, Benoît Noel
  • METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS
    Publication number: 20220411874
    Abstract: The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other blood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated is identified, evaluated or classified according to the method of the invention.
    Type: Application
    Filed: June 24, 2022
    Publication date: December 29, 2022
    Applicant: Genfit
    Inventors: Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
  • Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
    Patent number: 11519034
    Abstract: The present invention relates to a novel non-invasive method for the diagnosis of a non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, and/or liver fibrosis.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: December 6, 2022
    Assignee: Genfit
    Inventors: Remy Hanf, Genevieve Cordonnier, John Brozek
  • Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor
    Patent number: 11484517
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: November 1, 2022
    Assignee: GENFIT
    Inventors: Robert Walczak, Carole Belanger, Vanessa Legry, Benoît Noel, Emeline Descamps, Guillaume Vidal, Mathilde Walczak, Isabelle Delbaere
  • Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
    Patent number: 11478440
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: October 25, 2022
    Assignee: GENFIT
    Inventors: Robert Walczak, Carole Belanger, Vanessa Legry, Benoît Noel, Emeline Descamps, Guillaume Vidal, Mathilde Walczak
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 11400078
    Abstract: The present invention relates to a synergistic combination of active ingredients for use in the treatment of fibrotic diseases.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: August 2, 2022
    Assignee: GENFIT
    Inventors: Robert Walczak, Corinne Foucart, Philippe Delataille
  • Methods for diagnosing and evaluating non-alcoholic steatohepatitis
    Patent number: 11371098
    Abstract: The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other blood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated is identified, evaluated or classified according to the method of the invention.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: June 28, 2022
    Assignee: Genfit
    Inventors: Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
  • Methods of treatment of cholestatic diseases
    Patent number: 11331292
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: May 17, 2022
    Assignee: Genfit
    Inventor: Remy Hanf
  • Pharmaceutical compositions for combination therapy
    Patent number: 11191749
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: December 7, 2021
    Assignee: GENFIT
    Inventors: Dean Hum, Robert Walczak, Carole Belanger, Corinne Foucart
  • Methods of treatment of cholestatic diseases
    Patent number: 11185519
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: November 30, 2021
    Assignee: Genfit
    Inventor: Rémy Hanf
  • RORgamma modulators and uses thereof
    Patent number: 11160801
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 2, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 11103484
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 31, 2021
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Rorgamma modulators and uses thereof
    Patent number: 11077115
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: August 3, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases
    Patent number: 11052092
    Abstract: The present invention provides e.g. N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases or cholestatic diseases, such as e.g. arthitis and asthma.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: July 6, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak
  • Pharmaceutical compositions for combination therapy
    Patent number: 11033534
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 15, 2021
    Assignee: GENFIT
    Inventors: Corinne Foucart, Robert Walczak, Carole Belanger, Benoït Noel
  • RORgamma modulators and uses thereof
    Patent number: 10987351
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: April 27, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10905680
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: February 2, 2021
    Assignee: GENFIT
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille